Visus Therapeutics, Inc.

January is National Glaucoma Awareness Month. #DYK that glaucoma is often referred to as the “silent thief of sight?” Symptoms can begin gradually, and once vision is lost to #glaucoma, it cannot be restored. But early detection and treatment can help save your sight. Prevent Blindness recommends routine comprehensive eye exams as a crucial tool for detecting symptoms of glaucoma, including optic nerve damage, increased intraocular pressure, and vision loss. https://lnkd.in/eNszXh9

Visus Therapeutics, Inc. is proud to be a sponsor of the 2024 Healio Hawaiian Eye & Retina Meeting. Our team is looking forward to another exciting week engaging with ophthalmic industry leaders in such a beautiful environment. 🌸 🌅 #HawaiianEye2024

Visus Therapeutics, Inc. is thrilled to announce members of our leadership team are heading to Valley Isle for the 2024 Healio Hawaiian Eye and Retina Meeting. 🌸 🏝️ Every year we look forward to a week of world-class educators, networking opportunities, and the chance to discuss innovative technologies with peers and colleagues in #ophthalmology. Keep an eye out for #VisusTx attendees: Ben Bergo Rhett Schiffman MD MS MHSA James Burke Jehan Tamboowalla Julia Williams

Visus Therapeutics, Inc. is thrilled to announce our CEO Ben Bergo and members of our leadership team will be in San Francisco attending the 42nd Annual J.P. Morgan Healthcare Conference, January 8-11, 2024. If you would like to connect with us during the meeting, please contact Emily Schmitt, Visus Therapeutics, at Emily.Schmitt@VisusTx.com. #JPM2024 #JPM24

The positive topline results of our BRIO-I phase 3 pivotal trial evaluating BRIMOCHOL™ PF, our lead investigational candidate for the treatment of #presbyopia, were featured in a recent Ophthalmology Times article.   Authors Cecelia Koetting, OD FAAO DipABO and Elizabeth Yeu, MD, noted: “At 1, 2, 4, and 6 hours, Brimochol PF was superior to both carbachol and brimonidine monotherapies, with up to 51% of subjects meeting the preset FDA end point of a ≥ 15-letter gain from predose baseline without a ≥ 5-letter loss.” Link: https://lnkd.in/edpUKZhz

Visus Therapeutics, Inc. CEO Ben Bergo spoke with Ophthalmology Times during this year’s AAO meeting about the company’s BRIO-I and BRIO-II clinical trials for Brimochol™ PF, a once-daily drop in development for the treatment of #presbyopia.   Said Mr. Bergo: “We showed robust responder rates from early in the day, through to the latter parts of the day, to the latter time measurements in this study. Approximately 50% of subjects were able to graduate, from moderate to mild, or severe to mild, presbyopia, and achieve 2040 or better vision at 10 hours.”   Full interview: https://lnkd.in/gk_82Qdq

Congratulations to Zohra Womack, PMP on her 3rd work anniversary with Visus Therapeutics, Inc. As a Senior Director in Clinical Operations, Zohra leads our Phase 3 presbyopia program. Zohra’s warm and friendly style combined with strong ophthalmology clinical knowledge helps create a cohesive team that excels in clinical research. Zohra really shines in her ability to lead and inspire others and make true connections with co-workers, sites, and vendors. Please join us in celebrating and congratulating Zohra! #employeemilestone

A huge shout out to Aqsa Zahid, CPA on her 2-year anniversary at Visus Therapeutics, Inc.! As the Accounting Manager, Aqsa helps with the day-to-day operations of the accounting group including preparing monthly and annual financial statements. Her strong technical background has been instrumental in researching complex transactions to ensure proper accounting treatment and disclosures. Aqsa is such a pleasure to have on board and we appreciate her hard work and dedication. Please join us in celebrating and congratulating Aqsa! #employeemilestone

Julia Williams, Vice President of Clinical and Medical Affairs, of Visus Therapeutics, Inc., spoke with Healio during Eyecelerator @ AAO about the positive topline results from the phase 3 BRIO-I pivotal trial evaluating BRIMOCHOL™ PF, our lead investigational candidate for the treatment of #presbyopia.   “Our BRIO-I results showed that our Brimochol formulation met the primary and secondary endpoints, along with achieving the contribution of elements requirement for a fixed-dosed combination, and was well tolerated.”   Watch: https://lnkd.in/eqGmNmbk

We are thrilled to congratulate Esther Cuno, SPHR, GPHR, SHRM-SCP, our Vice President of Human Resources, on her fourth anniversary with us here at Visus Therapeutics, Inc. Esther is a powerhouse of HR knowledge and is the driving force behind our outstanding benefits program. She is highly dedicated to always going the extra mile to take care of each member of the Visus team and we are so grateful for her devoted leadership. Please join us in celebrating Esther! #employeemilestone